An improved benefit-risk profile of duvelisib in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma who received ≥2 prior therapies

Marco Montillo, Ian Flinn, Matthew Davids, Peter Hillmen, Julio Delgado, Bryone Kuss, Constantine Tam, Ulrich Jaeger, Paolo Ghia, Stephan Stilgenbauer, Stephanie Lustgarten, David Weaver, Hagop Youssoufian, Florence Cymbalista